BeiGene, Ltd. has lifted the veil over its antibody-drug conjugate (ADC) programs, touting best-in-class potential for three fast-follower molecules targeting B7-H3, CEACAM5 and B7-H4.
All three candidates are based on a linker-payload containing a topoisomerase I inhibitor (TOP1i), an approach first validated commercially by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?